Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · IEX Real-Time Price · USD
3.120
+0.130 (4.35%)
May 3, 2024, 9:37 AM EDT - Market open
Company Description
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Conduit Pharmaceuticals Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. David Joszef Tapolczay |
Contact Details
Address: 4995 Murphy Canyon Road, Suite 300 San Diego, California 92123 United States | |
| Phone | (760) 471 8536 |
| Website | conduitpharma.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001896212 |
| ISIN Number | US20678X1063 |
| Employer ID | 87-3272543 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Joszef Tapolczay | Chief Executive Officer and Director |
| Adam Sragovicz | Chief Financial Officer |
| Dr. Joanne M. Holland | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 18, 2023 | 424B3 | Prospectus |
| Dec 15, 2023 | EFFECT | Notice of Effectiveness |